Atreca, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- John A. Orwin
- Full Time Employees
- 90
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 835 Industrial Road South San Francisco CA United States of America 94070
- IPO Date
- Jun 20, 2019
- CIK
- 0001532346
- Website
- atreca.com
- Similar Companies
- Business
- Atreca, Inc. (BCEL) is a biotechnology company focused on discovering and developing novel antibody-based therapeutics targeting previously inaccessible cancer targets using its proprietary immune repertoire analytics platform. The company offers APN01, a novel antibody therapeutic candidate targeting a cancer-specific cell surface antigen; TRAACel, an analytics platform that captures and analyzes full-length antibody sequences from natural immune responses at single-cell resolution; and a pipeline of additional antibody-based product candidates derived from its technology, including those targeting unmet needs in oncology indications such as solid tumors.[ from previous search, assuming core info] Atreca operates primarily in the United States, with headquarters in Redwood City, California, where it was founded in 2010 as a private entity before going public. The company serves pharmaceutical and biotechnology partners through research collaborations and targets academic institutions, contract research organizations, and clinical trial sites in the immuno-oncology segment. In recent developments within the last two years, Atreca has undergone significant strategic shifts, including a corporate name change and ticker symbol update to better align with its evolving focus on precision oncology following a merger or reorganization event announced in late 2024. It has also pursued funding through equity offerings and partnerships to advance its lead candidates into clinical stages, with expanded operations into early-phase trials across North America and Europe. No major acquisitions were reported, but the company launched updated service offerings via its TRAACel platform to support external discovery efforts amid a broader biotech sector consolidation.
Why Is Atreca (BCEL) Stock Up 85% Today?
BCEL Stock Alert: Halper Sadeh LLC Is Investigating Atreca, Inc.
Atreca Announces Asset Purchase Agreement for Sale of Antibody-Related Assets and Materials to Immunome
Immunome to Acquire Antibody-Related Assets and Materials from Atreca
Atreca Reports Third Quarter 2023 Financial Results and Announces Further Reorganization to Support Exploration of Strategic Alternatives
Atreca Announces Agreement to Terminate Lease and Departure of Chief Financial Officer Herb Cross
Atreca (BCEL) Suspends Lead Drug Evaluation, Stock Falls 37%
Atreca Reports Second Quarter 2023 Financial Results and Announces Corporate Restructuring
3 Penny Stocks to Catapult You Into the Millionaires' Club
Atreca, Inc. (BCEL) Q4 2022 Earnings Call Transcript
Atreca to Host Fourth Quarter and Year End 2022 Conference Call and Webcast on March 29, 2023
Why Is Atreca (BCEL) Stock Up Today?
Atreca Locks In A Catalyst In The Oncology Space
Atreca to Present at Upcoming Investor Conferences
Atreca to Present at Upcoming Investor Conferences
Atreca to Present at Upcoming Investor Conferences
Cellino Announces Appointment of Abhijit Kulkarni, Ph.D. as Chief Operating Officer and Paulette Dillon as Chief Business Officer
Atreca to Present at Upcoming Investor Conferences
Atreca: Biotech With Promise Based On First Candidate ATRC-101
Atreca to Present at Upcoming Virtual Investor Conferences